|Patients and clinical setting||Comparison||Number of trials (n)||Outcome||Weighted mean difference (95% CI)|
|*ED = emergency department; ICU = intensive care unit; MDI = metered dose inhaler; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second. CI defined in glossary.|
|†All but 1 of the trials were clinical laboratory trials.|
|Adults and children in the ED or ICU||Nebuliser v MDI + spacer/holding chamber for short acting β2 agonists||9 (510)||FEV1||0.13 (−0.04 to 0.31)|
|11 (708)||Symptom scores||0.01 (−0.32 to 0.34)|
|Adults in the ED/ICU||Continuous v intermittent nebulisation for short acting β2 agonists||3 (137)||FEV1||0.07 (−0.63 to 0.77)|
|Adult and child inpatients||Nebuliser v MDI + spacer/holding chamber for short acting β2 agonists||3 (102)||FEV1||0.05 (−0.34 to 0.44)|
|2 (91)||Symptom scores||−0.04 (−0.46 to 0.37)|
|Adult outpatients||DPI v MDI + spacer/holding chamber for corticosteroids†||2 (44)||FEV1||0.09 (−0.33 to 0.51)|
|4 (257)||Symptom scores||0.08 (−0.47 to 0.62)|
Review: various devices for delivery of aerosol treatment can be equally efficacious
EBN Twitter Journal Club
The club runs like other journal discussion groups, except that the article and questions are posted on this blog and
the discussion about the article happens on Twitter.
How to participate >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.